NORML
APRIL 30, 2020
CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.” percent in 2016).” percent in 2016).”
Cannabis Law Report
MAY 10, 2022
Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. Queensland was the source of 51% of prescriptions between 2016 and 2021. We are aware of clinical trials in that space, but not strong evidence.”. The Guardian writes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaMD
JUNE 2, 2021
Non-uses were also asked what factors might cause them to consider adding medical marijuana to their treatment regime. More than 80% of survey respondents indicated strong interest in learning more information about a clinical trial, and more than half were interested in enrolling in a clinical trial.
Cannabis Law Report
MAY 10, 2022
Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows. Very few studies have also been done examining cannabis for the treatment of sleep disorders.
The Cannigma
MAY 19, 2021
Since 2016, the country has permitted the sale of CBD and some Japanese companies produce cannabidiol products as well. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. Shutterstock).
Cannabis Law Report
SEPTEMBER 1, 2021
The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. After Approval, It’s Off to Treatment Clinics.
Cannabis Law Report
MAY 29, 2022
Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. Trial of Psilocybin Versus Escitalopram for Depression , 384 New England J.
Expert insights. Personalized for you.
342 
Let's personalize your content